| DB ID | MyCo_3155 |
| Title | Bronchoalveolar lavage fluid and serum 1,3-β-D-glucan testing for invasive pulmonary aspergillosis diagnosis in hematological patients: the role of factors affecting assay performance |
| Year | 2020 |
| PMID | 33087853 |
| Fungal Diseases involved | Invasive pulmonary aspergillosis |
| Associated Medical Condition | Hematological patients |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The sample collection and research were approved by the Local Ethics Committee of the University Hospital Brno Czech Republic, Number 01-170920/EK. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Czech Republic |
| Cohort | In total, 172 unique episodes (from 152 adult patients) were analyzed. |
| Cohort No. | 152 |
| Age Group | 18-78 |
| P Value | None |
| Sensitivity | 0.783 |
| Specificity | 0.725 |
| Positive Predictive Value | 0.305 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | FDA Approved-Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
